Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center Randomized Double-Blind Placebo-Controlled Sequential Panel Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of MK0941 After Multiple Daily Administration of MK0941 Before Each Meal (q.a.c.) in Subjects With Type 2 Diabetes

Next Previous
Trial Profile

A Multi-Center Randomized Double-Blind Placebo-Controlled Sequential Panel Study to Assess the Safety Tolerability Pharmacokinetics and Pharmacodynamics of MK0941 After Multiple Daily Administration of MK0941 Before Each Meal (q.a.c.) in Subjects With Type 2 Diabetes

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MK 0941 (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Sponsors Merck & Co; Merck Sharp & Dohme

Most Recent Events

  • 25 Jun 2012 Actual patient number is 70 as reported by ClinicalTrials.gov.
  • 08 Apr 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 28 Feb 2008 The expected completion date is now Apr 2008 (fnal data collection date for primary outcome measure), reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top